Factors associated with a lower risk of developing lymphadenopathy included receiving only the first dose of the vaccine, patients aged 64 years or older, and being in an immunocompromised status. Rates of lymphadenopathy increased following the second Pfizer vaccine with rates reported of over 50%. Postvaccination lymphadenopathy was observed in 14.5% after a single dose of the Pfizer vaccine. In total, 1,980 study subjects had received the Pfizer vaccine. Two of the 15 trials involved Moderna's vaccine, three trials involved a combination of Pfizer and Moderna, and two of the trials did not indicate which vaccine was administered. Over 50% of the clinical trials (8/15) involved the Pfizer mRNA COVID-19 vaccine. Of the 2,057 patients included in these trials, 737 had vaccine-related lymphadenopathy. In total, 15 studies met inclusion criteria. Case studies and case series with fewer than 50 patients were excluded from analysis.Ī collection of case studies of vaccine-related regional lymphadenopathy was also compiled for diagnostic and therapeutic purposes. Studies were included only if there was a diagnosis of lymphadenopathy present under the following situations: palpable adenopathy in a patient with a symptomatic presentation, upon a breast screening examination, as an incidental finding during a screening exam, or while staging BC or during follow-up exams. They were searched from January through for association of the Pfizer, Moderna, Janssen, and AstraZeneca COVID-19 vaccines and the development of lymphadenopathy. Databases included PubMed, Ovid Medline, Scopus, CINHAL, Springer Nature, Science Direct, Academic Search Premier, the Directory of Open Access Journals, Google Scholar, and ResearchGate. This may be an especially concerning finding in patients with BC.Ī recent literature review examined the available evidence on vaccine-related lymphadenopathy and its clinical implications on BC diagnosis and management. With the widespread administration of the COVID-19 vaccines, reports have surfaced of the development of regional lymphadenopathy. The campaign to vaccinate the world against this deadly disease has been historic, with over 1 billion doses administered in the U.S. Vaccination has had a significant effect on reducing mortality and mortality from SAR-CoV2. COVID-19 has had devastating effects on the world population.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |